Use TigerSoft's Ranking Program to screen quickly for these stocks.
We reckon 70% of the time these stocks go up very significantly after such buying.
3 examples among San Diego companies are shown below.
CryoCor , Inc. is a medical technology company headquartered in San Diego, California.
The company is developing a technology platform in cardiac cryoablation therapy to treat heart arrhythmias,
which CryoCor believes will offer the cardiac electrophysiologist a new minimally invasive catheter-based
product to treeat atrial fibrillation, atrial flutter and other cardiac arrhythmias.
Halozyme Therapeutics, Inc. (Halozyme) is a biopharmaceutical company dedicated to the development and
commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility
markets. Halozyme has two United States Food and Drug Administration (FDA)-approved products, Cumulase,
a product used for in vitro fertilization (IVF), and Hylenex, an agent for drug and fluid infusion.
9 Parker
Suite 100
Irvine, CA 92618
Phone: 949-470-4751
Web Site: http://www.idm-biotech.com
IDM Pharma, Inc., a biopharmaceutical company, engages in the development of products that activate the
immune system to treat and control cancer. It is developing two types of products designed to destroy cancer
cells by activating innate immunity and prevent tumor recurrence by triggering a specific adaptive immune response.
The company has five products in clinical development. Its lead product candidate, Junovan, has completed a
Phase III clinical trial for the treatment of osteosarcoma, a bone cancer.
AP IDM Pharma to Meet With FDA Over
Junovan
Tuesday April 3, 1:25 pm ET
IDM Pharma to Meet With FDA Advisory Council May 9 Over Junovan
Application; Shares Soar
IRVINE, Calif. (AP) -- Biopharmaceutical company IDM Pharma Inc. said Tuesday it will meet
with a Food and Drug Administration advisory panel May 9 to discuss its application for
Junovan. The drug -- its lead candidate -- is aimed
at treating osteosarcoma, a type of malignant bone cancer, following surgical resection in
combination with chemotherapy.
IDM will meet with the Oncologic Drugs Advisory Committee, which will then give its
recommendation to the FDA.
